

Autoimmune Disorder

## A study of the long-term effects of fenebrutinib treatment in patients with lupus

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

<b>Trial Status</b> Terminated	<b>Trial Runs In</b> 11 Countries	<b>Trial Identifier</b> NCT03407482 2017-001764-37 GA30066
-----------------------------------	--------------------------------------	--

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT03407482 2017-001764-37 GA30066**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years & <= 76 Years

**Healthy Volunteers**  
No

---

This clinical trial was done to study a new medicine called, “fenebrutinib”, for the treatment of patients with “lupus”. Researchers wanted to know if fenebrutinib was safe over a long-term period when given to patients with lupus. One hundred and sixty patients took part in this study at 49 study centers in 11 countries.